Weinberg L, Collins N, Van Mourik K, Tan C, Bellomo R. Plasma-Lyte 148: A clinical review. World J Crit Care Med 2016; 5(4): 235-250 [PMID: 27896148 DOI: 10.5492/wjccm.v5.i4.235]
Corresponding Author of This Article
Laurence Weinberg, Associate Professor, Department of Anesthesia, Austin Hospital, Studley Rd, Heidelberg, Melbourne, Victoria 3084, Australia. laurence.weinberg@austin.org.au
Research Domain of This Article
Anesthesiology
Article-Type of This Article
Systematic Reviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Crit Care Med. Nov 4, 2016; 5(4): 235-250 Published online Nov 4, 2016. doi: 10.5492/wjccm.v5.i4.235
Plasma-Lyte 148: A clinical review
Laurence Weinberg, Neil Collins, Kiara Van Mourik, Chong Tan, Rinaldo Bellomo
Laurence Weinberg, Department of Surgery, Perioperative Pain Medicine Unit, University of Melbourne, Victoria 3084, Australia
Laurence Weinberg, Kiara Van Mourik, Chong Tan, Department of Anesthesia, Austin Hospital, Heidelberg, Melbourne, Victoria 3084, Australia
Neil Collins, Department of Anesthesia, Joondalup Health Campus, Joondalup, Perth 6027, Australia
Rinaldo Bellomo, Department of Intensive Care, Austin Hospital, Heidelberg, Melbourne, Victoria 3084, Australia
Author contributions: Weinberg L, Collins N and Van Mourik K performed the literature review and wrote the paper; Tan C and Bellomo R assisted in the writing of the manuscript.
Conflict-of-interest statement: Weinberg L is a recipient of research grants from Baxter Healthcare and is the Principle Investigator for the SPLIT-Major Surgery study. Bellomo R is a recipient of research grants from Baxter Healthcare and is a Principle Investigator for the SPLIT major surgery study. Baxter Healthcare is not involved in the design, collection of data, analyses, or interpretation of data from any Baxter sponsored fluid intervention study at the Austin Hospital. This review has been initiated and written independently of Baxter Healthcare or any other commercial institution.
Data sharing statement: No additional data available.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Laurence Weinberg, Associate Professor, Department of Anesthesia, Austin Hospital, Studley Rd, Heidelberg, Melbourne, Victoria 3084, Australia. laurence.weinberg@austin.org.au
Telephone: +61-3-94965000 Fax: +61-3-94596421
Received: March 27, 2016 Peer-review started: March 30, 2016 First decision: May 13, 2016 Revised: September 20, 2016 Accepted: October 5, 2016 Article in press: October 9, 2016 Published online: November 4, 2016 Processing time: 220 Days and 22.2 Hours
Abstract
AIM
To outline the physiochemical properties and specific clinical uses of Plasma-Lyte 148 as choice of solution for fluid intervention in critical illness, surgery and perioperative medicine.
METHODS
We performed an electronic literature search from Medline and PubMed (via Ovid), anesthesia and pharmacology textbooks, and online sources including studies that compared Plasma-Lyte 148 to other crystalloid solutions. The following keywords were used: “surgery”, “anaesthesia”, “anesthesia”, “anesthesiology”, “anaesthesiology”, “fluids”, “fluid therapy”, “crystalloid”, “saline”, “plasma-Lyte”, “plasmalyte”, “hartmann’s”, “ringers”“acetate”, “gluconate”, “malate”, “lactate”. All relevant articles were accessed in full. We summarized the data and reported the data in tables and text.
RESULTS
We retrieved 104 articles relevant to the choice of Plasma-Lyte 148 for fluid intervention in critical illness, surgery and perioperative medicine. We analyzed the data and reported the results in tables and text.
CONCLUSION
Plasma-Lyte 148 is an isotonic, buffered intravenous crystalloid solution with a physiochemical composition that closely reflects human plasma. Emerging data supports the use of buffered crystalloid solutions in preference to saline in improving physicochemical outcomes. Further large randomized controlled trials assessing the comparative effectiveness of Plasma-Lyte 148 and other crystalloid solutions in measuring clinically important outcomes such as morbidity and mortality are needed.
Core tip: Plasma-Lyte 148 is an isotonic, buffered intravenous crystalloid solution with a physiochemical composition that closely reflects human plasma. It is physiologically different to the commonly available crystalloids solutions such as Hartmann’s solution and sodium chloride (0.9%). Before using any crystalloid solution as fluid therapy, clinicians should have a fundamental understanding of each fluids specific physiological properties.
